All blog posts
Showing 12 out of 92 results
14 7月 2026
The EU Commission's new draft merger guidelines - key takeaways for pharma companies
16 6月 2026
2026 sees China's biotech scene continuing its ascent – but could US developments mean clouds on the horizon?
27 4月 2026
The EU Pharma Package is finally here – here's the settled position on key areas
12 3月 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
15 12月 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
09 12月 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
15 10月 2025
Venture investment in life sciences – Activity update & outlook (US & Europe)
24 9月 2025
Biopharma M&A activity – strategics continue to lead the way
28 8月 2025
The Thursday Investment Club: The case for later living
18 8月 2025
Pharma remains an enforcement focus in China – SAMR orders unwinding of a completed pharma deal
31 7月 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
22 7月 2025
Overview of EU regulatory and competition law in the Pharma sector
Showing 12 out of 92 results
View moreKey contacts
Laura Orlando
Managing Partner, Milan Office, Milan
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London